Eyeworld

120 | EYEWORLD | JULY 2021 by Nathan Radcliffe, MD Glaucoma Editor G UCOMA O phthalmology will see its first major live meeting since the pandemic started when the 2021 ASCRS Annual Meeting is held July 23–27 in Las Vegas, Nevada. The pres- ence of this annual meeting, usually held in the spring, being held in Las Vegas in July speaks to the unique times we are living in as our country emerges from the COVID-19 pandemic. Having endured, and occasionally enjoyed, more than a year of Zoom, Teams, and GoToMeeting, I am excited to return to the live meeting for- mat. While it has been nice to hear scientific exchange, there is something about bumping elbows with a colleague that is irreplaceable. A return to one-on-one, in-person conversations where you can query an experienced colleague about a surgical challenge you have encoun- tered is invaluable. As a member of the Glauco- ma Clinical Committee, I know that Glaucoma Day, led by Leon Herndon, MD, will be a great program, with more than a year of thoughtful anticipation and planning. Just as the live meeting will be reflective of our interesting times, this issue of EyeWorld is a product of our unique year, covering many topics that will help the modern ophthalmol- ogist and glaucoma specialist succeed. One of the topics we cover represents to me the biggest opportunity in the glaucoma space today: standalone MIGS. We have many patients on maximum tolerated medical therapy who would benefit from a safe intervention. Comprehensive ophthalmologists and glaucoma surgeons are now often expert angle surgeons, and we have several goniotomy and/or canaloplasty options that can provide significant IOP and medication reduction. In this issue, we also take a look at the rare occurrence of infection and glaucoma surgery and nuances of premium cataract surgery technologies in the context of glaucoma. As a glaucoma specialist who has been cautiously monitoring the premium cataract surgery space for the past 10 years, I am confident that now is the time for surgeons who have primarily been using monofocal technology to revisit the space. The full range of trifocal, enhanced depth of focus lenses with or without astigmatism correction are capable of delivering phenomenal outcomes that are suitable for many controlled glaucoma patients. As those of us in the fields of glaucoma and ophthalmology emerge from the pandemic, it is onward and upward. I am thrilled that ASCRS and EyeWorld are here to lead us into the next phase of our interesting times. Interesting times continue " A return to one-on-one, in-person conversations where you can query an experienced colleague about a surgical challenge you have encountered is invaluable."

• Blank Page
• Blank Page (1)